Literature DB >> 24710364

Adaptive methods help drug sponsors find best treatment dose.

Elie Dolgin.   

Abstract

Mesh：

Year:  2014        PMID： 24710364     DOI： 10.1038/nm0414-321

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success.

Authors:  Roger J Lewis; Kert Viele; Kristine Broglio; Scott M Berry; Alan E Jones
Journal:  Crit Care Med       Date:  2013-07       Impact factor: 7.598
  1 in total
  1 in total

1.  An Analysis of Sponsors/Collaborators of 69,160 Drug Trials Registered with ClinicalTrials.gov.

Authors:  Shruthi Muralidharan Keezhupalat; Ankeet Naik; Saurabh Gupta; Raghunathan Srivatsan; Gayatri Saberwal
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.